for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ベクトン・ディッキンソン・アンド・カンパニー

BDX

現在値

259.00USD

変化

-0.27(-0.10%)

出来高

1,117,980

本日のレンジ

258.99

 - 

262.22

52週レンジ

219.50

 - 

267.37

∙ 約20分前の相場を表示しています。

適時開示

Christopher DelOrefice To Join BD As Chief Financial Officer

Aug 11 (Reuters) - Becton Dickinson and Co <BDX.N>::CHRISTOPHER DELOREFICE TO JOIN BD AS CHIEF FINANCIAL OFFICER.BD - DELOREFICE SUCCEEDS CHRISTOPHER REIDY.

Christopher Reidy Announces Intent To Retire From Bd

Aug 5 (Reuters) - Becton Dickinson and Co <BDX.N>::CHRISTOPHER REIDY ANNOUNCES INTENT TO RETIRE FROM BD.BD - REIDY WILL JOIN BOARD OF DIRECTORS OF PLANNED DIABETES CARE SPINOFF.BD - CHRISTOPHER REIDY, EVP, CFO AND CHIEF ADMINISTRATIVE OFFICER HAS INFORMED CO OF HIS INTENT TO RETIRE AS HE REACHES RETIREMENT ELIGIBILITY.BD - REIDY WILL SERVE IN HIS CURRENT ROLE UNTIL A SUCCESSOR, WHO IS EXPECTED TO BE AN EXTERNAL CANDIDATE, IS IN PLACE.BD - REIDY WILL ASSIST NEW CFO IN TRANSITION.

Bd Announces Third Fiscal Quarter Results Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021

Aug 5 (Reuters) - Becton Dickinson and Co <BDX.N>::BD ANNOUNCES THIRD FISCAL QUARTER RESULTS; STRONG BASE GROWTH DRIVES BETTER PERFORMANCE IN QUARTER AND HIGHER GUIDANCE FOR FISCAL 2021.Q3 ADJUSTED EARNINGS PER SHARE $2.74.Q3 GAAP EARNINGS PER SHARE $1.72.Q3 EARNINGS PER SHARE ESTIMATE $2.44 -- REFINITIV IBES DATA.Q3 REVENUE $4.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.51 BILLION.EXPECTS FY 2021 REVENUES TO GROW ABOUT 16.5% TO 17.0% ON A REPORTED BASIS, AN INCREASE FROM THE PRIOR GUIDANCE OF 12% TO 14%.EXPECTS FISCAL YEAR 2021 CURRENCY-NEUTRAL REVENUE GROWTH OF ABOUT 14.0% VERSUS ITS PRIOR GUIDANCE OF 10% TO 12%.EXPECTS FY 2021 ADJUSTED DILUTED EPS TO BE BETWEEN $12.85 AND $12.95, AN INCREASE FROM THE PRIOR GUIDANCE OF BETWEEN $12.75 AND $12.85.BD- IN RECENT WEEKS CO SAW IMPACT ON ELECTIVE PROCEDURES FROM COVID DELTA VARIANT IN SOME U.S. STATES & ASSUMES SOME CONTINUATION OF THIS IN OUTLOOK.

Becton, Dickinson And Company Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

May 6 (Reuters) - Becton Dickinson and Co <BDX.N>::BECTON, DICKINSON AND COMPANY FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Bd Announces Intent To Spin Off Diabetes Care Business To Enhance Focus On Innovation And Priority Growth Markets

May 6 (Reuters) - Becton Dickinson and Co <BDX.N>::BD ANNOUNCES INTENT TO SPIN OFF DIABETES CARE BUSINESS TO ENHANCE FOCUS ON INNOVATION AND PRIORITY GROWTH MARKETS.BD - SPINOFF IS EXPECTED TO BE COMPLETED IN FIRST HALF OF CALENDAR YEAR 2022.BD - BD EXPECTS SPINOFF TO BE ACCOMPLISHED THROUGH A DISTRIBUTION OF STOCK IN NEWCO TO BD SHAREHOLDERS.BD - SPINOFF IS EXPECTED TO BE TAX-FREE FOR U.S. FEDERAL INCOME TAX PURPOSES.BD - EXPECTS TRANSACTION TO STRENGTHEN ITS MID-SINGLE-DIGIT REVENUE GROWTH AND DOUBLE-DIGIT TOTAL RETURN GROWTH PROFILE.

BD Reports Q2 Adjusted EPS $3.19

May 6 (Reuters) - Becton Dickinson and Co <BDX.N>::BD ANNOUNCES SECOND FISCAL QUARTER RESULTS; REAFFIRMS FISCAL 2021 GUIDANCE.Q2 ADJUSTED EARNINGS PER SHARE $3.19.Q2 GAAP EARNINGS PER SHARE $0.94.Q2 REVENUE $4.9 BILLION.BD - QTRLY BD'S COVID-19 TESTING SALES WERE $480 MILLION.Q2 EARNINGS PER SHARE VIEW $3.04, REVENUE VIEW $4.89 BILLION -- REFINITIV IBES DATA.

Bd Announces FDA 510(K) Submission For Bd Alaris™ System

April 26 (Reuters) - Becton Dickinson and Co <BDX.N>::BD ANNOUNCES FDA 510(K) SUBMISSION FOR BD ALARIS™ SYSTEM.

BD Announces Voluntary Recall Of Specified Lots Of Chloraprep Hi-Lite Orange 26 Ml Applicator In U.S. And U.S. Territories

April 20 (Reuters) - Becton Dickinson and Co <BDX.N>::BD ANNOUNCES THE VOLUNTARY RECALL OF SPECIFIED LOTS OF CHLORAPREP™ HI-LITE ORANGE™ 26 ML APPLICATOR IN THE UNITED STATES AND U.S. TERRITORIES DUE TO DEFECTIVE APPLICATOR.

FDA - Carefusion 303, Inc. Recalls Bd Alaris Pump Module Model8100 Due To Risk Of Stuck Or Unresponsive Keys

April 16 (Reuters) - FDA::FDA - CAREFUSION 303, INC. RECALLS BD ALARIS PUMP MODULE MODEL8100 DUE TO RISK OF STUCK OR UNRESPONSIVE KEYS.FDA - IDENTIFIED RECALL OF BD ALARIS PUMP MODULE MODEL 8100 AS A CLASS I RECALL.FDA - CAREFUSION 303 INC IS RECALLING ALARIS PUMP MODULE BECAUSE OF RISK OF KEYPAD LIFTING UP DUE TO FLUID ENTRY.FDA - THERE ARE NO REPORTS OF INJURIES OR DEATH ASSOCIATED WITH BD ALARIS PUMP MODULE MODEL 8100.

BD Expands Voluntary Recall Of ChloraPrep 3 mL Applicator

March 24 (Reuters) - Becton Dickinson and Co <BDX.N>::BD EXPANDS VOLUNTARY RECALL OF CHLORAPREP™ 3 ML APPLICATOR NATIONWIDE TO INCLUDE ALL U.S. STATES.BECTON DICKINSON - IS IMPLEMENTING GLOBAL PACKAGING CHANGE FOR 3 ML PRODUCT TO CORRECT ISSUE, EXPECTED TO BE AVAILABLE BY END OF APRIL IN U.S..BECTON DICKINSON AND CO - IS INSTRUCTING CUSTOMERS, DISTRIBUTORS TO DISCARD ALL REMAINING INVENTORY OF IMPACTED CHLORAPREP 3 ML APPLICATORS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up